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ABSTRACT
Introduction: In patients with infection and sepsis serum levels of Pancreatic 
Stone protein/regenerating protein I (PSP) are highly elevated. The origin of PSP 
during these conditions is presumably the pancreas, however, an intestinal origin 
cannot be excluded. Similarly, pancreatitis-associated protein (PAP) was identified 
in the pancreas. These proteins were also localized in intestinal organs. Here we aim 
to elucidate the bio-distribution of PSP and PAP in animal models of sepsis and in 
healthy humans.
Results: PSP and PAP responded to remote lesions in rats although the pancreatic 
response was much more pronounced than the intestinal. Tissue distribution of PSP 
demonstrated a 100-fold higher content in the pancreas compared to any other organ 
while PAP was most abundant in the small intestine. Both proteins responded to CLP 
or sham operation in the pancreas. PSP also increased in the intestine during CLP. 
The distribution of PSP and PAP in human tissue mirrored the distribution in the 
murine models. 
Materials and methods: Distribution of PSP and PAP was visualized by 
immunohistochemistry. Rats and mice underwent midline laparotomies followed by 
mobilization of tissue and incision of the pancreatic duct or duodenum. Standard 
cecum-ligation-puncture (CLP) procedures or sham laparotomies were performed. 
Human tissue extracts were analyzed for PSP and PAP. 
Conclusions: The pancreas reacts to remote lesions and septic insults in mice and 
rats with increased PSP synthesis, while PAP is selectively responsive to septic events. 
Furthermore, our results suggest that serum PSP in septic patients is predominantly 
derived through an acute phase response of the pancreas. 
INTRODUCTION
Pancreatic Stone Protein (PSP/regI) [1] and 
Pancreatitis-Associated Protein (PAP/regIII) [2, 3] have 
been identified several decades ago. Initially, their role 
was associated with pathological changes in the pancreas 
due to acute and chronic pancreatic inflammation [4]. 
Over time several hypotheses concerning their function 
were proposed [5, 6]. Briefly, after identification of PSP 
in the 1970s, it was assumed to inhibit stone formation 
based on its association with pancreatic depositions [7]. 
In the late 1980s PSP was independently found in islets 
[8, 9] and, due to its up-regulation after organ injury, was 
thought to have a regenerative effect and thus was named 
islet-derived regenerating protein (reg). During this early 
period, PSP was also named pancreatic thread protein, 
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lithostatin and regenerating protein I, while PAP was 
renamed regenerating protein III.
In the early 1990s PAP was identified during acute 
pancreatitis in rats and in humans [2, 3]. Both PSP and 
PAP were demonstrated to promote bacterial aggregation 
[10]. Further studies showed the presence of PSP and/or 
PAP in the brain [11, 12], the stomach [13], and intestine 
[14]. However, for most organs the function of PSP and 
PAP remains obscure.
Serendipitous observations in animal experiments 
led us to demonstrate PSP as an indicator of systemic stress 
in the rat [15]. To validate the clinical relevance for the 
PSP response we analyzed a cohort of trauma patients. We 
were able to demonstrate that serum PSP rises early after 
trauma in those patients that later develop infection and 
sepsis [16]. In contrast, well known parameters of general 
inflammation such as procalcitonin or Interleukin-6 were 
less sensitive. Other studies on sepsis [17], peritonitis [18], 
ventilator associated pneumonia [19, 20], or in pediatric 
patients [21, 22] demonstrated a predictive value for 
outcome.
Current research on the therapy of septic 
complications demonstrates that there is no commonly 
accepted algorithm for the treatment of patients and 
empirical antibiotic application varies significantly 
among centers [23]. Although recognized as a 
cornerstone for early treatment of sepsis [24], broadband 
antibiotic treatment may lead to an increase in multi-
resistant bacteria. Biomarkers helping to identify early 
inflammation and to better assess patients and guide the 
decision for an adequate and targeted therapy are therefore 
still needed [25]. Due to the complexity of physiological 
reactions a ‘one fits all’ biomarker does not exist, however, 
panels of biomarkers covering different diseases might be 
more useful [26]. Algorithms weighing the contribution of 
each biomarker require insights into regulation, functional 
mechanism, and reaction to specific conditions. Efficacy 
of PSP as such a biomarker is being evaluated in various 
clinical studies. A number of questions remain open: 
which organs mainly produce PSP and PAP, which organs 
are responsive to infected or septic conditions, and how 
can we explain the appearance of PSP in blood under both, 
healthy and pathological conditions. 
Here we show the bio-distribution of PSP and PAP 
in rats, mice, and humans. In animal experiments we 
show the reaction of various organs to tissue damage and 
a septic challenge. 
RESULTS
Bio-distribution of PSP and PAP in the healthy rat
To assess the potential for synthesis and release 
of PSP and PAP in the pancreas and intestine we first 
evaluated their distribution in rats. In healthy animals 
baseline levels in the pancreas were 90 ± 12 ng/mg 
(n = 19) for PSP and 6 ± 2 ng/mg (n = 20) for PAP I. The 
isoforms PAP II & III were hardly detectable (data not 
shown). In order to determine whether remote tissue injury 
causes an upregulation of these proteins, we measured the 
tissue contents of PSP and PAP I, II, & III in the intestinal 
tract. Ten segments of 10 cm intestine were harvested and 
proteins extracted. Figure 1A shows PSP at highest levels in 
the duodenum (segment 1, 2) with an intermittent rise in the 
jejunum. PAP I & III exhibited low levels in the proximal 
intestine (segment 1 to 6) and increased significantly in 
the ileum (segment 7 to 10). PAP II was not detectable in 
the entire intestine. The colon (segment 12) was negative 
for all proteins. While the stomach was positive for PSP 
and negative for all PAP isoforms, other organs such as 
kidney, liver, spleen, or lung were all negative for all tested 
proteins.
Immunohistochemical analysis of intestinal 
segments corroborated these findings (Figure 1B). 
While PSP is expressed in the duodenum, primarily in 
PANETH-like cells, PAP isoforms I & III localize mainly 
to enterocytes.
Does PSP & PAP respond to remote lesions?
In order to answer the question whether organs 
producing PSP and PAP respond to remote injury we 
started a pilot experiment by inflicting a small lesion in 
the distal duodenum, followed by sampling immediately, 
6, 12, and 24 hours later. We measured proteins from 
the lesion as well as from intact tissue 2 cm proximal 
and distal from the lesion. Supplementary Figure 1 
demonstrates that both PSP and PAP strongly increased - at 
all sampled sites - with a peak at twelve hours, indicating 
that the synthesis of these proteins responds to damage in 
the vicinity. 
In the next experiment we asked whether more 
distant lesions would induce an induction of PSP and 
PAP synthesis. For that purpose, we designed four groups 
of rat experiments receiving either a small lesion in the 
main duct of the pancreas, a lesion in the duodenum, 
a laparotomy only (sham operation), or a treatment 
mimicking anesthesia. Specimens were taken from the 
pancreas and the duodenum to determine synthesis and 
localization of PSP & PAP 6, 12, and 24 hours after 
surgery. 
First, we looked at the pancreas in response to the 
various lesions. Not surprisingly, PSP increased over 
24 hours in the pancreas in response to a pancreatic lesi 
on (Figure 2A). However, both a remote intestinal lesion 
as well as the sham laparotomy caused a similar increase 
in pancreatic synthesis of PSP. Furthermore, PSP in the 
pancreas was slightly elevated when the rat was subject 
to 20 minutes anesthesia only. PAP I, II & III reacted 
similarly to the various treatments with the exception 
of anesthesia which did not induce any increase in PAP 
isoforms (Figure 2B–2D).
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To corroborate our observations, we assessed 
pancreatic morphology and PSP and PAP I expression. 
When an intestinal lesion was incurred (Figure 3), the 
morphology of the pancreas did not change, however, 
PSP expression strongly increased from a punctate type 
to a strong homogenous staining (Figure 3G). PAP I, 
which is not detectable under baseline conditions, was 
only slightly visible after 12 hours (Figure 3D–3I). In 
case of a pancreatic lesion the reaction of PSP appeared 
much stronger in the vicinity of the lesion and also PAP I 
demonstrated a strong upregulation ( Figure 3M, 3N, 3P). 
Furthermore, after 24 hr duct cells turned positive for both 
PSP and PAP I (Figure 3O, 3R).
From these experiments we conclude that the 
pancreas responds to remote lesions
The same groups of animals were now assessed 
for changes in PSP & PAP expression in the intestine 
(Figure 4). PSP was increased in the sham, pancreatic, 
and intestinal lesion group while anesthesia did not invoke 
significant changes. The strongest increase was observed 
in the intestinal lesion group at 24 hrs indicating a local 
reaction. PAP I however, was strongly increased in the 
intestinal lesion group and to some extent in the pancreatic 
lesion group. Similarly, PAP III was strongly increased 
in the intestinal lesion group while pancreas and sham 
animals exhibited a moderate response. Taken together, 
both intestinal PSP and PAP seem to react preferentially 
to local damage and less to remote injury.
Again we corroborated findings by 
immunohistochemistry. Since the overall contents of PSP 
and PAP in the duodenum is much lower, only moderate 
changes could be observed (Figure 5) for both proteins. 
Figure 1: Representative example of tissue distribution of PSP and PAPI, II, III in the rat intestine. (A) Ten intestinal 
segments and the colon were collected and protein was extracted. PSP and PAP was quantified by isoform specific ELISA, expressed as 
ng/mg total protein. PAP refers to the left y-axis, PSP to the right x-axis. (B) Immunohistochemistry of PSP and PAPI & III in selected 
segments of the small intestine. PSP localizes to the duodenal part, predominantly to PANETH like cells. PAPI & III is more localized to 
enterocytes of the ileum.
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Do distant septic lesions induce a pancreatic 
response?
Since it is already known from human trials that PSP 
reacts sensitively to septic conditions we included a model 
of sepsis: the caecum-ligation-puncture model (CLP) 
which releases gut-bacteria into the peritoneum. PSP 
contents of various organs were determined in untreated 
controls, in sham operated animals, and the CLP procedure 
five days after induction. In the pancreas, PSP was already 
increased due to a general surgical trauma (sham group) 
while the addition of ligation and perforation of the 
caecum (CLP) did not significantly enhance the response 
any further (Figure 6A). A similar reaction was observed 
in the duodenum, jejunum, ileum, and caecum while the 
colon did not respond. In contrast to PSP, PAP expression 
in the pancreas responded more pronounced when treated 
with the full CLP procedure, while the sham operation 
caused an intermediate increase. All other organs did not 
show a selective response in terms of PAP expression 
(Figure 6B). These findings are corroborated by transcript 
levels of PSP, PAP, and major cytokines (TNFa and IL-6) 
or the chemokine MCP-1 (Supplementary Figure 2).
We conclude that in rats PSP responds predominately 
to surgical trauma (laparotomy and mobilization) while 
PAP I is distinguishing between surgical trauma and 
infection/sepsis.
How is the response of PSP and PAP in a mouse 
CLP model?
To evaluate whether similar control of PSP 
and PAP was active in mice we repeated the CLP 
experiments using a shorter period between induction of 
sepsis and sampling. In this model the pancreas reacted 
by a significant increase in PSP contents while the sham 
control was only slightly increased (Figure 7). In parallel 
serum PSP was significantly elevated in the sepsis group. 
In the intestine only the ileum demonstrated a significant 
PSP synthesis in the CLP group. Interestingly, the liver 
also reacted, albeit from very low levels to less than 1 
ng/mg protein, a concentration of more than 105 times 
lower than the pancreas. To verify whether there was 
a systemic inflammatory response we measured IL-6 
Figure 2: Response of the pancreas to a pancreatic ductal lesion (Pancreas), intestinal lesion (Intestine) laparotomy 
(Sham), or anaesthesia control (Anaesthesia). PSP and PAP isoforms were quantified immediately, 6, 12, and 24 hrs the operation. 
Tissue was homogenized, extracted, and the proteins determined for the different isoforms given in ng/mg total protein. Panel (A) PSP, (B) 
PAPI, (C) PAPII, and (D) PAPIII; (n = 5, mean ± SEM). 
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mRNA which was significantly upregulated in CLP mice 
while sham and controls did not display any changes 
(Supplementary Figure 3). We conclude that the pancreas 
senses the presence of a significant, infected lesion and 
is most likely the source of PSP release into the blood 
stream.
In addition, we also tested PSP and PAP mRNA 
levels in untreated mice. For PSP relative transcript levels 
were significantly higher in the pancreas (at least 105 fold) 
compared to any other tissue determined (Figure 8A). 
Similarly, mouse PAP (regIIIα) displayed the highest 
transcript levels in the pancreas compared to all other 
tested organs (Figure 8B). 
Which human organs produce PSP and PAP?
We have demonstrated so far that PSP increases in 
non-pancreatic, general inflammation and sepsis, hence 
we concluded that PSP responds to systemic triggers. 
Since PSP and PAP are also synthesized by other intestinal 
organs in mice and rats, we wanted to evaluate whether 
in humans they are primarily produced by the pancreas 
or whether other organs could contribute significantly to 
the release of PSP and PAP. Therefore, we quantitatively 
analyzed the contents of PSP and PAP in human organs 
from 16 autopsy cases. Figure 9 shows the contents of 
both proteins in the intestine, stomach, liver, and kidney. 
Importantly, the human pancreas was shown to produce 
PSP at more than an order of magnitude higher than any 
other organ (Figure 9A). Immunohistochemistry of PSP 
and PAP in intestinal organs support these determinations 
despite visible degradation, particularly in the pancreas 
(Supplementary Figure 4). Serum levels were quite similar 
to our normal values found in healthy subjects. In contrast, 
PAP was predominantly produced in the small intestine 
while the levels in the pancreas were quite low (Figure 9B). 
Furthermore, PSP was detected in homogenates from 
pancreata of two selected cases by western blot analysis. 
Figure 3: Morphology of lesions and their effect on the pancreas. Upper panel: site of lesion is the intestine, morphology of 
lesion at 0 (A) and 12 hrs (E). (B, F) H&E section of pancreas at 0 and 12 hrs. (C, D) Immunohistochemical staining of PSP and PAPI at 
0 hrs reflecting base-line levels. (G, I) Expression of PSP and PAPI 12 hrs after induction of a lesion.  Lower panel: site of lesion is the 
pancreas. (K, L, O) H&E section demonstrating the morphology of the lesion at 0, 6, and 24 hrs. (M, N) immunohistochemistry of the 
pancreas localizing PSP and PAPI 6 hrs after the lesion. Note overlapping response. (P) PSP at 24 hrs in the vicinity of the lesion. Similar 
distribution pattern was observed for PAPI. (Q, R) Significant expression of PSP and PAPI in ductal cells, see also inset in Q. Bar = 200 
mm (A, B, E, F, K, L, O, P), Bar = 50 mm (C, D, G, I, M, N, Q, R).
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Compared to recombinant PSP at 16 KDa, most of the 
extracted PSP had an approximate molecular weight of 
14 KDa which is a known cleavage product lacking the 
11 terminal amino acids. In contrast to the known 
propensity of rodent PSP to form insoluble fibers after 
cleavage, the extracted PSP was soluble (Figure 9C). So far 
the molecular forms of PSP have mainly been characterized 
in pancreatic juice. We therefore analyzed serum from 
three patients that developed septic complications 
postoperatively (Figure 9D). On western blot analysis 
preoperative serum did not show any bands while 16kDa 
bands were clearly visible in serum during sepsis. 
We also explored the potential of mRNA-
levels despite the susceptibility to degradation in dead 
tissue. Surprisingly, when PSP-mRNA was detected 
by quantitative PCR we found levels similar to ‘fresh’ 
pancreatic biopsy tissue (Supplementary Figure 5) plotted 
as ∆Ct relative to 18S RNA. PSP-mRNA in the small 
intestine was much lower, reflecting its corresponding 
protein levels. PAP in contrast, was most abundant in the 
small intestine, primarily in the jejunum. The unexpectedly 
high levels of PSP in the pancreas led us to look at the 18S 
RNA to which transcript levels are normalized. Indeed, Ct 
values indicated that in autopsy cases the retrieval of RNA 
yields only about 1% of fresh biopsy indicating advanced 
degradation.
From the bio-distribution in ‘healthy’ subjects 
(not septic) we conclude that the major source of PSP is 
from the pancreas while PAP is mainly produced by the 
intestine. 
DISCUSSION
Here we show the response of the pancreas to 
local and systemic injury with respect to production of 
PSP and PAP, two proteins known to be highly induced 
during pancreatitis. We observed increased production 
and secretion when a lesion was induced remote from the 
pancreas. This supports the concept that this organ, similar 
to the liver can act as an acute phase organ. Furthermore, 
we also show the quantitative distribution of these proteins 
in healthy human organs. 
We and others have shown in several clinical studies 
that PSP/reg is significantly upregulated in patients with 
septic complications. Since it has been known for a long 
time that PSP is not only produced in the pancreas but 
also in intestine and stomach it was never clear where it 
was released from during a septic episode. We therefore 
Figure 4: Intestinal levels of PSP, PAPI ,II, III in response to a pancreatic ductal lesion (Pancreas), intestinal lesion 
(Intestine), laparotomy (Sham), or anaesthesia control (Anaesthesia). Tissue from a defined site was collected, homogenized, 
and quantified for (A) PSP, (B) PAPI, (C) PAPII, (D) PAP III. Note different axis levels for the various isoforms; (n = 5, mean ± SEM).
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Figure 5: Morphology of intestinal lesion and tissue distribution of PSP & PAPI. (A) H&E staining of the lesion at 0 hrs. 
(B, C) Immunohistochemistry at 0 hrs for PSP and PAPI. Inset in (B) demonstrates normal expression of PSP in PANETH like cells. 
Arrowhead points to the cross-section of a piece of blue suture material to tie the knot. Immunohistochemistry of intestinal sections after 
induction of a pancreatic lesion. Minimal expression of PAPI at 6 hrs (E) and 12 hrs (F) and PSP at 12 hrs (G).
Figure 6: Organ-specific response of PSP and PAPI to a septic event in the rat. Organs from an experiment after caecum-ligation 
and puncture were analyzed for tissue contents. (A) PSP, (B) PAPI. Organs tested are indicated at the bottom. Values are given in box-&-
whisker-plots (median, min, max). Open boxes: base-line values, light grey boxes: sham-laparotomy, dark grey boxes: CLP. **p < 0.01 
between untreated and CLP;  n = 5.
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set out to clarify the relative distribution of PSP and PAP 
in rodents and human subjects and tried to evaluate the 
origin of PSP in experimental models. It has to be stated 
up front that an absolute proof for which organ is primarily 
secreting these proteins (during sepsis) is currently not 
possible as the complexity of promoters driving tissue 
specific expression (e.g. in pancreatic acinar cells versus 
intestinal PANETH cells) has not been clarified yet, and 
hence genetic (knock-out/knock-in) models may not give 
an unambiguous answer. 
Recent evidence from clinical studies indicates 
that PSP is highly increased and secreted into blood at 
Figure 7: Organ-specific response of PSP to a septic event in the mouse. Organs measured are indicated at the bottom. Values 
are given in ng/mg tissue or ng/ml serum, and shown as box-&-whisker-plots (median, min, max). Open boxes: base-line values, light grey 
boxes: sham-laparotomy, dark grey boxes: CLP. Significant differences between untreated and CLP treated mice: *p < 0.05, **p < 0.01; 
n = 5.
Figure 8: Relative transcript levels of PSP and PAP in the mouse at base-line in various organs. RNA was extracted from 
healthy mice and transcripts were determined by qPCR. Organs are given at the bottom. All transcript levels were normalized relative to 
pancreatic transcript levels. Please note logarithmic x-axis; n = 5.
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the onset of sepsis [16]. Normally PSP is secreted into 
the pancreatic duct system along with zymogens to 
promote digestion. In case of a pancreatic injury PSP is 
also increased and, presumably due to tissue damage, 
is released into the interstitium and blood. This appears 
to be a passive effect based on damaged cells which is 
presumed to be the reason for elevated serum amylase and 
lipase levels during pancreatitis. Upregulation of these 
enzymes by enhanced synthesis is not observed, rather the 
opposite: there is a tendency for a reduced amylase/lipase 
content during pancreatitis. In contrast, PSP synthesis is 
strongly increased in acinar cells and hence explains the 
appearance of significant serum levels.
These observations lead us to believe that beyond 
passive release, PSP is actively stimulated by factors 
that may be local or systemic. As such, it is known that 
PSP can be induced by cytokines, e.g. IL-6. The function 
of PSP has been controversial, particularly since it was 
assumed for a long time that PSP is a secretory protein 
released into the duct and hence would exert its function in 
the intestine. These studies revealed a potential to inhibit 
stone formation, as a regenerative factor for β-cells, or 
as a protein promoting aggregation of intestinal bacteria. 
A discussion of these functions is beyond the focus of 
this report; however, the function of PSP in blood still 
remains open. We have demonstrated that neutrophilic 
granulocytes can be activated by PSP [16]. Yet it remains 
uncertain whether there is a direct interaction with a 
membrane-bound receptor as binding of PSP required a 
high concentration. This indicates that PSP might require 
a binding partner that subsequently induces activation. 
While responsive to septic incidents, other triggers 
Figure 9: Tissue distribution of PSP (A) and PAP (B) in human autopsy cases after unnatural death. Organs indicated below the x-axis 
were analyzed by ELISA. PSP and PAP contents are expressed as ng/mg tissue protein. Pancreatic PSP content was significantly higher 
(p < 0.001) than any other tissue. Serum values are indicated in ng/ml. N = 16 cases. (C) Western blot analysis of pancreatic extracts for the 
presence of PSP in two autopsy cases. Extraction was performed as indicated in material and methods. T = total protein loaded. S = soluble 
protein fraction, P = insoluble (pellet) fraction. Recombinant human PSP was loaded as indicated. (D) Western blot analysis of serum PSP 
of three patients before surgery and after surgery when PSP contents were highest. Size of marker on the left, 2 ng recombinant PSP on the 
right.  
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may also increase the presence of PSP in blood. As an 
example, it has been reported that diabetes [27, 28], renal 
failure and liver cirrhosis [29] may also induce elevated 
levels of PSP.
Quantitative data on the tissue distribution of PSP 
and PAP has not been available until now and, although 
merely descriptive, these data might give reference for 
future studies to evaluate potential sources of these 
proteins under physiological and pathological conditions. 
As expected PSP levels were highest in the pancreas in 
humans and rodents and increased after experimental 
septic events in mice and rats. In the intestine a consistent 
pattern was observed in the three species tested. This 
points to a conserved function in the gastrointestinal 
tract. Also, there was a selective increase during sepsis 
in segments of the small intestine while other organs 
did not react. This reaction is not only local but induces 
a systemic response that includes upregulation of PSP in 
‘remote’ organs. Our initial experiments tested whether 
small lesions affecting one part of an organ only would 
induce systemic response and synthesis of PSP and PAP 
in another organ. Particularly, we assessed whether the 
pancreas could be a sensor for such lesions and thereby 
act as an organ centrally releasing PSP as part of an acute 
phase response. Indeed, the pancreas contains the highest 
amount of PSP, is activated to release PSP, and senses 
organ damage, particularly when associated with septic 
complications. 
Our quantitative findings corroborate numerous 
reports on localization of PSP in individual organs 
where PSP has been described [11–14]. Also PAP 
(regIII) determinations are quite consistent with previous 
reports [14]. One caveat is the existence of multiple 
isoforms demonstrating selective regulation. This is best 
exemplified in the small intestine of the rat where PAP 
II is not expressed while PAP I & III are clearly and 
consistently expressed in certain segments. Incidentally, 
PAP II is the only known isoform that does not form 
insoluble fibrils after tryptic cleavage of the N-terminal 
peptide [30]. We assume that localization and function are 
tightly correlated; hence, PAP II might exert a different 
role than the other isoforms in a non-redundant way. A 
further example is mouse regIIIγ, which appears to be 
involved in bacterial colonization [31]. 
In summary, we provide quantitative tissue specific 
data of PSP and PAP isoforms in humans, rats, and 
mice. Baseline production of PSP is several magnitudes 
higher in the pancreas than any other organ while PAP 
is predominantly expressed in the small intestine. Under 
systemic stress both PSP and PAP are predominantly 
increased in the pancreas of rats and mice. 
MATERIALS AND METHODS
Reagents
All reagents were of analytical grade. If not 
otherwise stated they were purchased from SIGMA-
Aldrich, Buchs, Switzerland.
ELISA
Enzyme linked immunosorbent assays (ELISAs) 
detecting PSP & PAP isoforms in humans, rats, and mice 
were performed with antibodies produced by our lab as 
previously described [15, 16, 32, 33]. In brief, the open 
reading frame was cloned into a Pichia pastoris vector 
in frame with a signal directing the polypeptide to be 
secreted into medium [34]. The positive clones were 
amplified and tested for efficiency of secretion. One clone 
was further expanded for production of the polypeptide. 
Concentration and purification was performed on an Akta 
System (Pharmacia, Dübendorf Switzerland) using a 
cation exchanger with a lithium chloride/pH gradient. 
For generation of antibodies, the purified 
polypeptides were injected into guinea pigs and rabbits 
using Friend’s complete and incomplete adjuvans. Animals 
reaching a high titer (usually 1:100′000 dilution to detect 
0.5mg/ml coated on an ELISA plate) were then terminally 
bleed. Subsequent purification of IgG was performed on 
proteinA columns (Pharmacia, Dübendorf, Switzerland). 
This procedure was followed for the antibodies used in 
the study. 
The sandwich ELISA followed a common 
procedure: guinea pig IgG was coated over night, washed 
and blocked with TBS/BSA, followed by incubation with 
sample or standards. Subsequently the secondaryrabbit 
antibody was incubated, followed by a phosphatase-
conjugated anti-rabbit antibody (SIGMA, Buchs, 
Switzerland). The plate was developed with a phosphatase 
substrate and OD 405 measured on a Tecan ELISA Reader.
Immunohistochemistry
Paraffin embedded formalin-fixed tissue was 
sectioned at 3mm. To deparaffinize, the sections were 
carried through an increasing alcohol series. For antigen 
demasking the sections were boiled in citrate for 
20 minutes and subsequently allowed to cool. The sections 
were then blocked overnight at 4°C prior to incubation with 
the primary antibody in a humidified chamber. Detection 
of the primary antibody followed according to the manual 
of the ABC Vector stain detection kit (Vector Laboratories, 
Burlingame, Ca, USA). The sections were counterstained 
with Haemalaun and covered by a glass slip. The formalin-
fixed human tissue was deparaffinized in a PT-link and 
stained on an Autolink from Dako (Denmark). Antibodies 
were used as described [15, 16, 32, 33].
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Isolation of RNA and RT-PCR
RNA from pancreata and other organs followed 
the procedure described earlier [15]. Total RNA was 
quantified by Nanodrop 2000 (Thermo Scientific, Zug, 
Switzerland) and a quality control was performed 
by a Bioanalyzer 2100 (Agilent, Basel Switzerland). 
Subsequently, 1 μg total RNA was reverse transcribed and 
used for real-time polymerase chain reaction (PCR) as 
described previously [15, 30] or with a newly established 
method using the Precellys®24 Dual homogenizer (VWR, 
Dietikon, Switzerland) with MagNA Lyser Green Beads 
from Roche Applied Science (Basel, Switzerland). In 
brief, a small piece of snap frozen tissue was transferred 
to a tube containing beads, 650 ml of Lysis buffer (Qiagen, 
Hilden, Germany) was added and the tube immediately 
homogenized in a Precellys shaker for 30 seconds at 
6000 rpm. RNA was extracted following the Qiagen 
RNeasy Mini Kit extraction protocol with an on column 
DNase digestion. Purified RNA was reverse transcribed 
into cDNA using qScript™ cDNA SuperMix of Quantabio 
(Beverly, MA, USA) according to the manufacturer’s 
protocol. Quantitative PCR was then performed on an 
ABI 7500 FAST sequence detection system (Applied 
Biosystems, Zug, Switzerland). 
Animal studies
All animal studies were executed according to 
Swiss animal protection laws. Protocols were subjected 
to review by the Veterinary Offices and approved by the 
Ethics committee of the Canton of Zurich. The study on 
mice was performed on biopsies purchased from PHENOS 
(Hannover, Germany).
Rat I (injuries to pancreas and intestine)
Male rats (Sprague Dawley) were purchased from 
Harlan (Horst, the Netherlands) and allowed to adapt 
for two weeks in our SPF-facility with access to food 
and water ad libitum. Prior to the operation, rats were 
starved overnight. Following induction of anesthesia by 
Sevoflurane inhalation, the animals were randomly sorted 
into one of four groups: 1) anesthesia only (anesthesia 
group), 2) median laparotomy only (sham group), 3) 
induction of a small lesion of the major pancreatic duct 
(pancreas group), or 4) induction of a small lesion of the 
small intestine (intestine group). The length of procedure 
in group 3 and 4 was approximately 20 minutes, therefore 
the animals of group 1 and 2 were also kept under 
anesthesia for a similar time period. All procedures were 
performed under a sterile hood on a heating plate (37°C). 
To harvest plasma and tissue rats were sacrificed and small 
pancreatic specimens were excised from the site of injury 
and from a site remote to the damage (6, 12, and 24 hrs 
after surgery). Intestinal tissue was directly collected from 
the lesion site as well as 2 cm proximal and distal of the 
lesion. All tissue specimens were frozen at -80°C. Animal 
tissues were used to quantify PSP and PAP by isoform-
specific ELISA and to detect the proteins by histology.
Rat II (CLP-Model)
Induction of sepsis in rats was performed according 
to standard procedures for the caecum ligation and 
puncture (CLP) model as reported in [31]. Briefly: Rats 
were anaesthetized with isoflurane. Following laparotomy 
the caecum was localized, mobilized, and briefly moved 
(sham group) or ligated by a 5.0 suture (CLP group). The 
caecum was then punctured with a 19-G needle (CLP 
group). The laparotomy was closed by a suture and the 
rats were then allowed to wake up on a heating pad. All 
rats were sacrificed five days after surgery and animal 
plasma and organ tissues (all abdominal organs, heart, 
lungs, muscle, brain) were used for analysis of PSP and 
PAP (ELISA, PCR and histology). 
Mouse CLP Model
The CLP model in mice (C57BL/6) was performed 
in accordance with the rat CLP experiments. Tissue was 
harvested after 6 hours.
Human study (protein expression in healthy 
tissues and in plasma)
Organs of sixteen cases succumbed to unnatural 
death were collected by the medical examiner. Tissue 
samples were immediately frozen in liquid nitrogen and 
stored at −80°C. Dissection was performed 8 ± 2 hours 
after death. The cases appeared to be healthy prior to 
death. Analysis of material from human subjects by the 
medical examiner (C.P., medico-legal autopsies) was 
performed as requested by the inquiring authorities, 
respecting guidelines of the Canton de Vaud, Switzerland. 
The samples collected for this study are routinely collected 
during autopsy for histological purposes. No ethical 
approval was necessary to collect samples and perform 
analyses in the collected cases.
In the last part of this study serum from three 
patients that developed septic complications was used 
for PSP quantification, approved by the Kantonale 
Ethikkommission Zurich and registered under https://
clinicaltrials.gov/ (NCT01258179).
Statistical methods
For most experiments the group size was five 
animals. Comparison between two groups was performed 
by Student’s t-tests, whereby p < 0.05 was considered 
statistically significant. The distribution within a group 
was assessed and checked for Gaussian distribution. For 
Oncotarget30173www.impactjournals.com/oncotarget
comparisons between three groups one-way ANOVA 
was performed with Dunnetts post-hoc test to identify 
differences between individual groups. The statistical 
software GraphPad Prism (San Diego Ca, USA) was used 
for all calculations.
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